Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800894 | 0.88 | MDM4 (0.33) | MDM4TP53CASP3CXCR2MDM2 | |
| SCHEMBL10045802 | 0.81 | TNF (0.35) | MDM4TP53CASP3HDAC1HDAC2 | |
| SCHEMBL800983 | 0.80 | TNF (0.33) | — | |
| SCHEMBL10045805 | 0.80 | TNF (0.35) | MDM4TP53CASP3HDAC1HDAC2 | |
| SCHEMBL801052 | 0.70 | CASP3 (0.43) | MDM4TP53CASP3EPHX2MDM2 | |
| SCHEMBL12237521 | 0.64 | MDM4 (0.50) | MDM4TP53CASP3HDAC1HDAC2 | |
| SCHEMBL21848147 | 0.64 | CXCR2 (0.39) | MDM4TP53CASP3CXCR2EPHX2 | |
| SCHEMBL8453044 | 0.63 | KMT2A (0.56) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL12677657 | 0.62 | KMT2A (0.52) | MDM4TP53CASP3EPHX2MDM2 | |
| SCHEMBL10187006 | 0.62 | KMT2A (0.52) | MDM4TP53CASP3EPHX2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | MDM4 524/4885TP53 41/4885CASP3 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.